Tourmaline Bio Inc.

NASDAQ: TRML · Real-Time Price · USD
22.56
0.17 (0.76%)
At close: Aug 15, 2025, 1:07 PM

Tourmaline Bio Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
39K 33K 6K 623K
Gross Profit
-39K -33K -6K -623K
Operating Income
-89.73M -45.41M -19.7M -47.51M
Interest Income
16.52M 3.29M n/a n/a
Pretax Income
-73.21M -42.12M -19.7M -47.83M
Net Income
-73.21M -42.12M -19.7M -904
Selling & General & Admin
22.75M 13.04M 2.17M 692.00
Research & Development
66.98M 32.37M 17.53M 212.00
Other Expenses
n/a n/a n/a 46.88M
Operating Expenses
89.73M 45.41M 19.7M 46.88M
Interest Expense
n/a n/a n/a 326K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
89.73M 45.41M 19.7M 47.51M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
25.35M 4.75M 20.34M 10.88M
Shares Outstanding (Diluted)
25.35M 4.75M 20.34M 10.88M
EPS (Basic)
-2.89 -8.87 -0.97 -0.00
EPS (Diluted)
-2.89 -8.87 -0.97 -0.00
EBITDA
-89.73M -45.38M -19.7M -46.88M
EBIT
-73.21M -42.12M -19.7M -47.51M
Depreciation & Amortization
-16.52M 33K 6K 623K